Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: Glycoprotein llb/llla inhibitors, clopidogrel, or both?

Vascular Health and Risk Management

Volumn 2, Issue 1, 2006, Pages 39-48

  Silva, Matthew A ^a   Donovan, Jennifer L ^a,c   Gandhi, Pritesh J ^b   Volturo, Gregory A ^c  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ALEXION PHARMACEUTICALS   (United States)

^c UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

Abciximab; Acute coronary syndromes; Clopidogrel; Eptifibatide; Glycoprotein IIb IIIa inhibitors; Tirofiban

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; GELATINASE B; HEPARIN; HIRULOG; INTERCELLULAR ADHESION MOLECULE 1; LOW MOLECULAR WEIGHT HEPARIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYOGLOBIN; PLACEBO; THROMBOPLASTIN; THROMBOXANE A2; TIROFIBAN; TROPONIN I; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; BLOOD TRANSFUSION; BOLUS INJECTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; MAINTENANCE DRUG DOSE; META ANALYSIS; MONOTHERAPY; MORTALITY; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRACTICE GUIDELINE; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; RISK REDUCTION; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOPLASTIN TIME; TREATMENT PLANNING; UNITED STATES;

ACUTE DISEASE; ANGIOPLASTY, BALLOON, CORONARY; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GUIDELINE ADHERENCE; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; REGISTRIES; RESEARCH DESIGN; RISK FACTORS; SYNDROME; TICLOPIDINE;

EID: 33646108123     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: 10.2147/vhrm.2006.2.1.39     Document Type: Review

References (45)

1. Batchelor WB, Tolleson TR, Huang Y, et al. 2002. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation, 106:1470-6.
2. Bhatt DL. 2003. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov, 2:15-28.
3. Braunwald E, Antman EM, Beasley JW, et al. 2002. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002: summary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the management of patients with unstable angina). Circulation, 106: 1893-1900.
4. Cannon CP. 2005. What is the optimal timing of clopidogrel in acute coronary syndromes? Crit Pathways in Cardiol, 4:46-50.
5. [CAPTURE] CAPTURE Investigators. 1997. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet, 349: 1429-35.
6. Cook-Mills J. 2002. VCAM-1 signals during lymphocyte migration: role of reactive oxygen species. Mol Immunol, 39:499-508.
7. Dalby M, Montalescot G, Bal dit Sollier C, et al. 2004. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel: Results of the platelet activity extinction in non-Q-Wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J Am Coll Cardiol, 43:162-8.
8. Egashira K. 2003. Molecular mechanisms mediating inflammation in vascular disease: special reference to monocyte chemoattractant protein-1. Hypertension, 41:834-41.
9. [EPIC] The EPIC Investigators. 1994. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med, 330:956-61.
10. [EPILOG] EPILOG Investigators 1997. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med, 336:1689-96.
11. [ESPRIT] ESPRIT Investigators; Enhanced Suppression of the Platelet IIb/ IIIa Receptor with Integrilin Therapy. 2000. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet, 356:2037-44.
12. Gurbel PA, Bliden KP, Zaman KA, et al. 2005. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets (CLEAR-PLATELETS) study. Circulation, 111:1153-9.
13. Gurbel PA, Galbut B, Bliden KP, et al. 2002. Effect of eptifibatide for acute coronary syndromes: rapid versus late administration - therapeutic yield on platelets (The EARLY Platelet Substudy). J Thromb Thrombolysis, 14:213-19.
14. Hoekstra JW, Roe MT, Peterson ED, et al. 2005. Early glycoprotein IIb/ IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns. Acad Emerg Med, 12:431-8.
15. Iiyama K, Hajra L, Iiyama M, et al. 1999. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res, 85:199-207.
16. [IMPACT-II] IMPACT-II Investigators. 1997. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet, 349: 1422-88.
17. Jiang Y, Beller DI, Frendl G, et al. 1992. Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol, 148:2423-8.
18. Kandzari DE, Berger PB, Kastrati A, et al; ISAR-REACT Study Investigators. 2004. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol, 44:2133-6.
19. Lau WC, Gurbel PA, Watkins PB, et al. 2004. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation, 109:166-71.
20. Mahoney EM, Jurkovitz CT, Chu H, et al; TACTICS-TIMI 18 Investigators. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. 2002. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA, 288:1851-8.
21. Maksimowicz-McKinnon K, Bhatt DL, Calabrese LH. 2004. Recent advances in vascular inflammation: C-reactive protein and other inflammatory biomarkers. Curr Opin Rheumatol, 16:18-24.
22. Mehilli J, Kastrati A, Schühlen H, et al; Intracoronary Stenting and Antithrombotic Regimen - Rapid Early Action for Coronary Treatment (ISAR-REACT) Study Investigators. 2004. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation, 110:3627-35.
23. Mehta SR, Yusuf S, Peters RJ, et al; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. 2001. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 358:527-33.
24. Müller I, Besta F, Schulz C, et al. 2003. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost, 89:783-7.
25. O'Shea JC, Buller CE, Cantor WJ, et al; ESPRIT Investigators. 2002. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA, 287:618-21.
26. Patti G, Colonna G, Pasceri V, et al. 2005. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation, 111:2099-106.
27. Peterson ED, Pollack J, Charles V, et al; National Registry of Myocardial Infarction (NRMI) 4 Investigators. 2003. Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4. J Am Coll Cardiol, 42:45-53.
28. Ridker PM, Rifai N, Pfeffer M, et al. 2000. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation, 101:2149-53.
29. Roffi M, Chew DP, Mukherjee D, et al. 2001. Platelet glycoprotein IIb/ IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation, 104: 2767-71.
30. Sack M. 2002. Tumor necrosis factor-alpha in cardiovascular biology and the potential role for anti-tumor necrosis factor-alpha therapy in heart disease. Pharmacol Ther, 94:123-35.
31. Saucedo JF, Aude W, Pacheco R, et al. 2005. Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The PharmacoDynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin [DEACON] study). Am J Cardiol, 95:1453-6.
32. Silva M, Gandhi PJ. 2004. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years? J Clin Pharm Ther, 29:497-510.
33. Simoons ML; GUSTO IV-ACS Investigators. 2001. Effect of glycoprotein IIb/ IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet, 357:1915-24.
34. Smith J, Sidney C, Dove JT, et al. 2001. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) - executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol, 37:2215-38.
35. Sonel AF, Good CB, Mulgund J, et al; CRUSADE Investigators. 2005. Racial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes: insights from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines?). Circulation, 111:1225-32.
36. Steinhubl SR, Ellis SG, Wolski K, et al. 2001. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation, 103:1403-9.
37. [PRISM] Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. 1998. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med, 338:1498-1505.
38. [PRISM-PLUS] Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. 1998. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med, 338:1488-97.
39. [PURSUIT] PURSUIT Trial Investigators. 1998. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med, 339:436-43.
40. [RESTORE] RESTORE Investigators. 1997. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation, 96:1445-53.
41. Topol EJ, Lincoff AM, Kereiakes DJ, et al. 2002. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med, 113:1-6.
42. Viedt C, Vogel J, Athanasiou T, et al. 2002. Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kappaB and activator protein-1. Arterioscler Thromb Vasc Biol, 22:914-20.
43. Yamamoto T, Eckes B, Mauch C, et al. 2000. Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop. J Immunol, 164:6174-9.
44. Yusuf S, Mehta SR, Zhao F, et al; Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators. 2003. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation, 107:966-72.
45. Yusuf S, Zhao F, Mehta SR, et al; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. 2001. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 345:494-502.